- Home
- DHY vs ARCT Comparison
DHY vs ARCT Comparison
Compare DHY & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHY | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 217.7M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DHY | ARCT |
|---|---|---|
| Price | $1.75 | $7.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | ★ 660.6K | 443.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.74 | $5.85 |
| 52 Week High | $2.16 | $24.14 |
Technical Indicators
Market Signals| Indicator | DHY | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 46.79 |
| Support Level | $1.75 | $6.70 |
| Resistance Level | $2.05 | $7.88 |
| Average True Range (ATR) | 0.02 | 0.40 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 37.50 | 52.01 |
Price Performance
Historical ComparisonAbout DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.